Low Diagnostic Yield of Non-Invasive Imaging In Angiogram-Negative Subarachnoid Hemorrhage
J Joshi, S Prabhakaran, S John
angiogram, ct, hemorrhagic stroke, mri, non-perimesencephalic
J Joshi, S Prabhakaran, S John. Low Diagnostic Yield of Non-Invasive Imaging In Angiogram-Negative Subarachnoid Hemorrhage. The Internet Journal of Neuromonitoring. 2008 Volume 6 Number 1.
Subarachnoid hemorrhage (SAH) is an acute, life threatening condition afflicting a significant portion of the emergency room emergency cases and overall patient population.1 Though many understand the condition as a life threatening condition, SAH is a macrocosm in of itself that encompasses multiple types of hemorrhagic strokes affecting the Sub-Arachnoid region, with varying degrees of urgency and severity. Many prominent seminal studies attempted to classify the types of SAH based on either the prognosis, anatomic origins, pathophysiology, or underlying morbidity and mortality.2-9 They established the foundation for future studies attempting to determine key correlations and patterns among clinical prognosis, associated clinical symptoms, and either an anatomic or pathophysiologic finding. In current practice, it is common to ascertain SAH patient prognosis upon clinical imaging of either a conventional or DSA angiogram, a computed tomography angiography (CTA) scan of the head, or a magnetic resonance angiography (MRA) of the head. SAH patients whose initial angiogram does not locate a bleeding source are often classified as having perimesencephalic hemorrhages. However, many patients do not fit into this benign picture and are non-perimesencephalic, angiogram-negative SAH (NPAN-SAH). Though the conventional angiogram remains the gold standard for diagnosis, multiple non-invasive imaging tests, beyond a second angiogram, are often performed in the acute evaluation of NPAN-SAH.
When patients are admitted for SAH, it is important to monitor for secondary hematoma formation, hydrocephalus, and hemodynamic stability. These associative conditions are typically more severe in patients with DSA positive imaging for an aneurysm location.10 If a bleed source, such as an aneurysm, is located, the appropriate treatment can be initiated. Yet, if no bleeding etiology is determined, identifying a potential source becomes one of the principle concerns.11-14 This risk often precipitates the decision to repeat imaging tests or initiate different modalities.
We determine if such additional non-invasive imaging improves diagnostic yield in identifying a bleeding source, or better characterizing the nature and sub-type of the SAH.
With IRB approval, we retrospectively reviewed 226 non-traumatic SAH patients admitted to our institution from January 1, 2007 to June 1, 2009 who underwent SAH imaging protocol at a single tertiary care institution. Patients eligible for the study met the following inclusion criteria per medical records: (1) at least 18 years of age; (2) either non-aneurysmal or indeterminant cause of SAH per initial DSA; (3) the patient was admitted within the acute phase interval of condition; and (4) the patient was treated according to the hospital protocol.
In our study, we began by abstracting imaging data from the medical records detailing the results of the study. We evaluated the DSA study first, and subsequently moved on to CTA and MRA studies, if available. Studies that provided inconclusive results were evaluated on a PACS (picture archiving and communication system) by independent neurologists. Factors considered upon image evaluation include the anatomic location of the bleed, any hematoma formation, and any subsequent bleeding patterns suggestive of rebleeding. We aggregated data on the number of images performed and the number of imaging modalities.
Of the 226 SAH patients, 45 (19.9%) had no aneurysm on initial angiography. Of these angiogram-negative SAH patients, 12 (26.7%) were perimesencephalic SAH and 33 (73.3%) were NPAN-SAH. There were 4 deaths (8.9%, 95% CI 3.0-21.3), all in NPAN-SAH cohort with 2 (4.4%) deaths due to re-bleeding. Forty-one (91.1%) had repeat angiography within two weeks and 3 (6.7%) had a third angiogram at long-term follow-up. All 33 (100%) NPAN-SAH had repeat angiography. Forty-one (91.1%) had at least 1 CTA of the head, 16 (35.6%) 2 CTAs, and 5 (11.1%) had > 2 CTAs. Forty-two (93.3%) had MRI and MRA of brain and cervical spine, 20 (44.4%) had additional thoracic MRI, and 18 (40.0%) had additional MRI of the entire spine. An average of 3.2 non-invasive studies were performed on each patient. In these 142 additional non-invasive studies, there was no additional diagnostic yield in finding the source of SAH.
Patients with non-perimesencephalic angiogram-negative SAH have worse prognosis compared to patients with perimesencephalic SAH. Our study demonstrates that additional non-invasive neuro-imaging provides no diagnostic yield in either patient population.
The diverse clinical presentation of SAH sub-types makes it difficult to ascertain a set clinical work-up for all patients. And among individual patients, the risk of rebleeding and clinical deterioration warrants continual evaluation and monitoring. Yet our study shows that subsequent testing is not necessarily efficacious. Prior studies demonstrate utility in repeating DSA imaging, but many remain inconclusive about the value of repeat CTA and MRA.15-22 It is likely that the large disparity in clinical results stem from the uniquely different study types. Having little to no definitional consensus as to what constitutes a specific type of SAH creates random disparity in each study’s categorization of the patient populations’ conditions. Though a few studies have attempted to systematically evaluate the decision to undergo a particular type of study or series of imaging studies23,24, these studies are largely predicated on the results derived in previously published studies.23
Many prior studies have lead to seemingly inconclusive evidence perhaps due to over generalizing. Of late, many studies have focused on studying SAH of a particular anatomic region, a certain blood pattern, or only certain imaging modalities in a specific context.25-33 Limiting the context of the study to just a certain aspect of angiogram negative patients allows one to better identify key patient presentations making the decision to proceed with imaging modality situation specific.27,29,32 While the pathophysiology has yet to be fully elucidated, from a clinical standpoint, envisioning each patient’s condition as a unique disease allows the physician to make patient specific decisions. Many other cerebrovascular conditions demonstrate different behaviors based on the etiology and anatomic region; and patient management reflects the nuances.34
In clinical management of angiogram negative SAH, far too often the decision simplifies to determining how significant the risk of re-bleeding is. Though key studies have identified anatomic regions where angiograms are likely to be missed, or where venous-based SAH occur, practical clinical management is reluctant to rely just on those studies.1-3,10,14,18,26,35 Studies that corroborate clinical imaging with further surgical evaluation will help strengthen the validity of certain imaging results, but it is difficult to find studies with significant enough patient populations to be heavily relied upon.36
Conversely, rather than looking for situation-specific patterns to help guide decision making, better imaging modalities can be used to increase the specificity of a negative angiogram finding.37 But better technology may not be able to fully eliminate the risk and uncertainty inherent in deciding whether to order further imaging. Part of the issue is the physicians’ fear that by not undergoing additional imaging, he or she did not do a comprehensive enough job in patient management. Therefore, extending the standardized protocol of SAH management into imaging based decisions will help alleviate the dilemma faced by physicians.27
Limitations in the study include the relatively small sample size. Additionally, we did not distinguish the types of studies from the number of studies. Our focus was to evaluate the absolute number of subsequent studies and assess the utility. Further value could have been gained from assessing the relative value of a subsequent CTA relative to an MRA or DSA. We did not distinguish if certain patient types or anatomic presentations automatically warranted more extensive imaging work-up relative to other presentations either.
Further study must focus on identifying key correlations in an anatomic- or presentation- specific manner. The inconclusiveness and disparity among prior studies assumes that angiogram negative SAH is either one condition, or composed of one or two condition. The spectrum of acuity, mortality, and associative conditions implies that angiogram negative SAH should be viewed as a much broader disease that present as many unique conditions.